United States - English - NLM (National Library of Medicine)

mylan institutional inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 25 ug - hypothyroidism: levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression:  levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: - levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. - levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficie

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.1 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.1 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.2 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.15 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.075 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.05 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.025 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Ireland - English - HPRA (Health Products Regulatory Authority)

aristo pharma gmbh - levothyroxine sodium anhydrous ep - tablet - levothyroxine sodium